Join our email list to stay up to date on the latest Amyloidosis news.

The white paper contains the highest priorities and a research framework for the systemic amyloidosis diseases. This consensus document was developed through a rigorous process with the participation of 71 international experts from academic, clinical, regulatory, patient advocacy, health policy, industry, and other key areas. This publication is intended to identify, improve and accelerate a drug development pathway for the systemic amyloidosis diseases.

*

*

*









*